ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,998,607 | +18.1% | 168,259 | +52.8% | 0.35% | +16.1% |
| Q2 2023 | $5,080,068 | +15.0% | 110,120 | +0.0% | 0.30% | +8.3% |
| Q1 2023 | $4,415,654 | +73.9% | 110,116 | +100.6% | 0.28% | +56.8% |
| Q4 2022 | $2,539,441 | +9.5% | 54,884 | -2.0% | 0.18% | +15.8% |
| Q3 2022 | $2,320,000 | -30.5% | 56,018 | +0.1% | 0.15% | -27.6% |
| Q2 2022 | $3,339,000 | -18.2% | 55,960 | -0.5% | 0.21% | +7.7% |
| Q1 2022 | $4,082,000 | -13.5% | 56,215 | +0.1% | 0.20% | -4.9% |
| Q4 2021 | $4,721,000 | -9.9% | 56,144 | -3.4% | 0.20% | -10.1% |
| Q3 2021 | $5,239,000 | -7.3% | 58,092 | -2.0% | 0.23% | -4.2% |
| Q2 2021 | $5,651,000 | -16.9% | 59,271 | -0.7% | 0.24% | -22.2% |
| Q1 2021 | $6,799,000 | – | 59,712 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |